Mesa Laboratories (NASDAQ:MLAB - Get Free Report) is expected to release its Q4 2025 earnings data before the market opens on Wednesday, May 28th. Analysts expect Mesa Laboratories to post earnings of $2.75 per share and revenue of $61.90 million for the quarter.
Mesa Laboratories Stock Performance
MLAB traded down $1.96 during trading hours on Friday, hitting $102.68. The company's stock had a trading volume of 42,219 shares, compared to its average volume of 39,912. Mesa Laboratories has a fifty-two week low of $83.68 and a fifty-two week high of $155.12. The company has a current ratio of 0.71, a quick ratio of 0.53 and a debt-to-equity ratio of 0.61. The firm has a market capitalization of $560.12 million, a PE ratio of -2.22 and a beta of 0.97. The company has a 50-day simple moving average of $115.26 and a 200 day simple moving average of $126.32.
Mesa Laboratories Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Monday, June 16th. Stockholders of record on Friday, May 30th will be given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.62%. The ex-dividend date of this dividend is Friday, May 30th. Mesa Laboratories's dividend payout ratio (DPR) is presently -172.97%.
Wall Street Analysts Forecast Growth
A number of equities analysts recently issued reports on the company. Wall Street Zen cut Mesa Laboratories from a "strong-buy" rating to a "buy" rating in a report on Friday. Wells Fargo & Company decreased their target price on Mesa Laboratories from $120.00 to $100.00 and set an "underweight" rating for the company in a research report on Friday.
Read Our Latest Report on MLAB
Insiders Place Their Bets
In related news, CEO Gary M. Owens sold 21,000 shares of the business's stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $123.91, for a total transaction of $2,602,110.00. Following the completion of the transaction, the chief executive officer now owns 43,337 shares of the company's stock, valued at approximately $5,369,887.67. The trade was a 32.64% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.40% of the company's stock.
Hedge Funds Weigh In On Mesa Laboratories
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jacobs Levy Equity Management Inc. bought a new stake in shares of Mesa Laboratories during the 1st quarter valued at $335,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Mesa Laboratories by 4.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,068 shares of the medical instruments supplier's stock worth $364,000 after acquiring an additional 143 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Mesa Laboratories by 3.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 19,977 shares of the medical instruments supplier's stock worth $2,370,000 after purchasing an additional 685 shares during the period. Finally, Royal Bank of Canada increased its stake in Mesa Laboratories by 1.2% in the first quarter. Royal Bank of Canada now owns 30,772 shares of the medical instruments supplier's stock valued at $3,652,000 after acquiring an additional 353 shares during the last quarter. 90.60% of the stock is currently owned by institutional investors.
About Mesa Laboratories
(
Get Free Report)
Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.
Read More
Before you consider Mesa Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesa Laboratories wasn't on the list.
While Mesa Laboratories currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
